Syntara Ltd.

The launch of emerging therapies like BESREMi (PharmaEssentia and AOP Orphan Pharmaceuticals), INCB057643 (Incyte), XPOVIO (Karyopharm Therapeutics), RYTELO (Geron), REBLOZYL (Bristol Myers Squibb), Navtemadlin (Kartos Therapeutics), Pelabresib (Novartis), and others is going to shift the myelofibrosis market. LAS VEGAS, Sept. 3, 2025 /PRNewswire/ -- DelveInsight's Myelofibrosis Market Insights report includes a comprehensive understanding of current treatment practices, emerging myelofibrosis drugs, market share of individual therapies, and current and forecasted myelofibrosis market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan). Myelofibrosis Market Summary The total myelofibrosis treatment market size in the leading markets (the US, EU4, UK, and Japan) was USD 2.2 billion in 2024. The United States accounts for the largest market size of myelofibrosis, in comparison to EU4 (Germany, Italy, France, and Spain) and the UK, and Japan. Based on DelveInsight's assessment in 2024, the 7MM had approximately 56K patient pool (prevalent cases) of myelofibrosis. Key myelofibrosis companies, including PharmaEssentia, AOP Orphan Pharmaceuticals, Incyte, Karyopharm Therapeutics, Geron, Bristol Myers Squibb, Kartos Therapeutics, Novartis, Merck, Telios Pharma, Ryvu Therapeutics, Sumitomo Pharma, Syntara, Disc Medicine, Menarini Group, and others, are actively working on innovative myelofibrosis drugs. Some of the key myelofibrosis therapies in clinical trials include BESREMi (ropeginterferon alfa-2b-njft/P-1101), INCB057643, XPOVIO (NEXPOVIO/selinexor/KPT-330), RYTELO (imetelstat), REBLOZYL (luspatercept/ACE-536), Navtemadlin (KRT-232), Pelabresib (DAK539), Bomedemstat (IMG-7289/MK-3543), TL-895, RVU120 ( SEL-120), TP-3654 (nuvisertib), SNT-5505 (PXS-5505), DISC-0974, ELZONRIS (tagraxofusp/SL-401), and others. These novel myelofibrosis therapies are anticipated to enter the myelofibrosis market in the forecast period and are expected to change the market. By 2034, among all the therapies, the highest revenue is expected to be generated by OJJAARA/OMJJARA. Discover which myelofibrosis therapies are expected to grab the largest market share @ Myelofibrosis Market Report Key Factors Driving the Growth of the Myelofibrosis Market Novel Therapies Drive Myelofibrosis Treatment Advancements Currently, four JAK inhibitors have been approved by the US FDA for the treatment of myelofibrosis, including JAKAFI (ruxolitinib), INREBIC (fedratinib), VONJO (pacritinib), and OJJAARA (momelotinib). No drug therapy can cure myelofibrosis. As myelofibrosis primarily affects older adults, stem cell transplantation is not a treatment option for most myelofibrosis patients. The launch of another JAK inhibitor, BESREMi, will further change the dynamics of the myelofibrosis market. Rich clinical pipeline and emerging non-JAK approaches driving the myelofibrosis landscape Beyond JAK inhibitors, active clinical development includes BET inhibitors (Incyte's INCB057643; Novartis' Pelabresib), XPO1 inhibitor (Karyopharm Therapeutics' XPOVIO), Telomerase inhibitor (Geron's RYTELO), MDM2 protein inhibitor (Kartos Therapeutics' Navtemadlin), Tyrosine kinase inhibitors (Telios Pharma's TL-895), PIM1 kinase inhibitor (Sumitomo Pharma's TP-3654), LOX inhibitor (Syntara's SNT-5505), and others, raising market potential by promising new label expansions, second-line options, and higher-value therapies should any prove to be disease-modifying. An aging population & increasing incidence with better survival Myelofibrosis primarily affects older adults; population aging increases the absolute number of patients. As treatments improve symptoms and (in some cases) survival, prevalent patient pools grow, supporting longer-term market demand. In the US in 2024, the 70+ years of age group had the highest number of cases, accounting for approximately 60% of the total prevalent cases, while the ≤39 years of age group accounted for just ~2%. Diagnostic & genomic testing improvements are driving myelofibrosis patient pool, leading to the growth of myelofibrosis market Wider use of molecular profiling (JAK2, CALR, MPL, and others) enables earlier and more accurate MF diagnosis and better patient stratification for targeted therapies. This both expands the diagnosed population and helps match patients to appropriate, often higher-value, treatments. Myelofibrosis Market Analysis JAK inhibitors have become the cornerstone of treatment for patients with myelofibrosis, offering significant benefits such as spleen reduction, symptom relief, and improved quality of life, which can also extend survival in those with advanced disease. All approved JAK inhibitors primarily target JAK2, particularly the wild-type form, but they differ in their activity against other JAK family members. For instance, JAKAFI myelofibrosis inhibits both JAK1 and JAK2; INREBIC selectively inhibits JAK2 while sparing JAK1 and also affects FLT3 and other targets; VONJO myelofibrosis inhibits JAK2 while sparing JAK1 but additionally impacts FLT3, IRAK, and ACVR1; and OJJAARA, approved through a different pathway, targets JAK1/JAK2 and ACVR1, mainly for myelofibrosis patients with anemia. These varying mechanisms lead to distinct patient outcomes. JAKAFI myelofibrosis continues to see strong demand and is expected to grow further, maintaining its position as the standard of care in myelofibrosis. Myelofibrosis will remain the largest segment of JAKAFI's patient population until polycythemia vera cases eventually increase. However, market growth may be limited due to patent expirations of key therapies, with JAKAFI patents set to expire in 2027 for Novartis and 2028 for Incyte, presenting potential opportunities for competitors. In response, Incyte is exploring combination trials with novel drugs to extend JAKAFI's therapeutic lifespan. Learn more about the treatment options for myelofibrosis @ Myelofibrosis Therapy The myelofibrosis treatment landscape offers significant opportunities for innovation, focusing on several key areas: Treating Lower-Risk Patients: Developing safe and effective therapies for patients with lower-risk myelofibrosis, allowing for earlier and more favorable interventions. Enhancing First-Line Treatments: Improving existing first-line therapies for intermediate- to high-risk patients through novel drugs or combination strategies. Managing Cytopenia: Developing targeted therapies to address cytopenia, a significant unmet need in patient care. Myelofibrosis Competitive Landscape The myelofibrosis clinical trial pipeline includes several drugs in mid- and late-stage development that are expected to enter the market during the forecast period. The emerging landscape offers a diverse range of therapeutic alternatives for treatment, including XPOVIO (Karyopharm Therapeutics), Elitracet (Takeda/Keros Therapeutics), Navtemadlin (Kartos Therapeutics), Pelabresib (Novartis), INCB057643 (Incyte), Bomedemstat (Merck), and others, all of which are used in various lines of treatment. The expected launch of these therapies is expected to have a further positive impact on the market. INCB57643 is an orally administered small molecule. Bromodomain and extra-terminal (BET) proteins act as epigenetic readers that control the expression of key oncoproteins implicated in the development of myelofibrosis and other hematologic malignancies, including B-lymphoma-2, nuclear factor kappa, and c-Myc. In a prior Phase I/II clinical trial, the oral BET inhibitor INCB057643, tested both as a monotherapy and in combination with ruxolitinib, demonstrated favorable tolerability and promising clinical activity in patients with advanced cancers. In its Q2 2025 financial report, the company announced that the combination of INCB057643 with ruxolitinib and INCB57643 (a JAK1/JAK2 and BET inhibitor) is currently being evaluated in a Phase II trial for myelofibrosis. RYTELO (imetelstat) is an investigational telomerase inhibitor that targets telomerase, selectively eliminating malignant stem and progenitor cells in the bone marrow, which drive diseases like myelodysplastic syndromes (MDS) and myelofibrosis. By blocking the proliferation of these malignant cells, imetelstat supports the recovery of healthy bone marrow and blood cell production and has shown disease-modifying effects and clinical benefits in Phase III trials for myelofibrosis. This mechanism sets imetelstat apart from other approved or investigational therapies for these blood cancers. In January 2025, Geron reported achieving 75% enrollment in the Phase III IMpactMF trial, which is comparing imetelstat to Best Available Therapy (BAT) in intermediate-2 or high-risk myelofibrosis patients who have relapsed or are refractory to JAK inhibitor treatment. Elritercept is a late-stage investigational activin inhibitor aimed at treating anemia associated with hematologic malignancies, including MDS and myelofibrosis. It is currently undergoing Phase II evaluation in patients with myelofibrosis. In December 2024, Keros Therapeutics presented updated data from this ongoing Phase II trial at ASH 2024. Additionally, in December 2024, Takeda announced an exclusive licensing agreement with Keros to further develop, manufacture, and commercialize elritercept globally, excluding mainland China, Hong Kong, and Macau. The anticipated launch of these emerging myelofibrosis therapies are poised to transform the myelofibrosis market landscape in the coming years. As these cutting-edge myelofibrosis therapies continue to mature and gain regulatory approval, they are expected to reshape the myelofibrosis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about new myelofibrosis treatment, visit @ Myelofibrosis Treatment Market Recent Developments in the Myelofibrosis Market In July 2025, Incyte announced that the Phase I data in patients with myelofibrosis as monotherapy and in combination with ruxolitinib are anticipated in the second half of 2025. In June 2025, QIAGEN and Incyte announced a new global collaboration to develop a novel diagnostic panel to support Incyte's extensive portfolio of investigational therapies for patients with myeloproliferative neoplasms (MPNs), including Incyte's monoclonal antibody INCA033989. In January 2025, Karyopharm Therapeutics stated that it expects to report top-line results from the Phase III SENTRY trial in the second half of 2025, which could represent a potentially transformative opportunity to establish a new treatment paradigm in myelofibrosis. What is Myelofibrosis? Myelofibrosis is a rare blood cancer marked by the accumulation of scar tissue, or 'fibrosis', in the bone marrow. This excess scar tissue prevents the bone marrow from producing enough healthy blood cells. It belongs to a group of blood cancers called 'myeloproliferative neoplasms (MPNs)', in which the blood cells produced by the bone marrow grow and function abnormally. When myelofibrosis arises independently, without being caused by another bone marrow disorder, it is referred to as primary myelofibrosis. In other cases, it can develop from another MPN, such as polycythemia vera or essential thrombocythemia. When this occurs, it is called secondary myelofibrosis, sometimes specifically termed post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis. Myelofibrosis Epidemiology Segmentation The myelofibrosis epidemiology section provides insights into the historical and current myelofibrosis patient pool and forecasted trends for the leading markets (the US, EU4, UK, and Japan). It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The myelofibrosis market report proffers epidemiological analysis for the study period 2020–2034 in the leading markets (the US, EU4, UK, and Japan) segmented into: Total Prevalent Cases of Myelofibrosis Type-specific Cases of Myelofibrosis Myelofibrosis Cases Based on Risk Stratification Age-specific Prevalent Cases of Myelofibrosis Myelofibrosis Cases Based on Molecular Alterations Download the report to understand which factors are driving myelofibrosis epidemiology trends @ Myelofibrosis Treatment Drugs Scope of the Myelofibrosis Market Report Myelofibrosis Therapeutic Assessment: Myelofibrosis current marketed and emerging therapies Myelofibrosis Market Dynamics: Conjoint Analysis of Emerging Myelofibrosis Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Myelofibrosis Market Unmet Needs, KOL's views, Analyst's views, Myelofibrosis Market Access and Reimbursement Discover more about myelofibrosis drugs in development @ Myelofibrosis Clinical Trials Table of Contents Related Reports JAK Inhibitors Market JAK Inhibitors Market Size, Target Population, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key JAK inhibitors companies, including Pfizer, AbbVie, Galapagos, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, Gilead Sciences, Reistone Biopharma, Jiangsu Hengrui Medicine Co., MaxiNovel Pharmaceuticals, among others. Myelofibrosis Clinical Trial Analysis Myelofibrosis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key myelofibrosis companies, including Geron Corporation, Merck, Ryvu Therapeutics SA, Morphic Therapeutic, iOnctura, Pharmaxis, Nippon Shinyaku, Active Biotech, Incyte Corporation, Sumitomo Pharma America, Inc., Cellenkos, Disc Medicine, among others. Polycythemia Vera Market Polycythemia Vera Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key polycythemia vera companies, including Incyte, Novartis, PharmaEssentia, AOP Orphan Pharmaceuticals, Protagonist Therapeutics, Merck (Imago BioSciences), Italfarmaco, Ionis Pharmaceutical, Silence Therapeutics, Perseus Proteomics, AbbVie, Johnson & Johnson Innovative Medicine, Mabwell (Shanghai) Bioscience, Disc Medicine, GluBio Therapeutics, among others. Multiple Myeloma Market Multiple Myeloma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key multiple myeloma companies, including Sanofi, Karyopharm Therapeutics, AbbVie, Takeda Pharmaceutical, Celgene, Bristol-Myers Squibb, RAPA Therapeutics, Pfizer, Array Biopharma, Cellectar Biosciences, BioLineRx, Celgene, Aduro Biotech, ExCellThera, Janssen Pharmaceutical, Precision BioSciences, Takeda, Glenmark (Ichnos Sciences SA), Poseida Therapeutics, Molecular Partners AG, Chipscreen Biosciences, AbbVie, Genentech (Roche), Janssen Biotech, Nanjing Legend Biotech, Merck Sharp & Dohme Corp., among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Connect with us on LinkedIn | Facebook | Twitter Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Founding members will help shape the company's scientific and technology roadmap to deliver more efficient, automated, and cost-effective CDMO solutions, enabling biotech partners to bring transformative cell therapies to patients faster. PRINCETON, N.J., Aug. 28, 2025 /PRNewswire/ -- Made Scientific, a leading U.S.-based contract development and manufacturing organization (CDMO) specializing in cell therapies, today announced the formation of its Scientific Advisory Board (SAB) with the appointments of Miguel Forte, M.D., Ph.D., Paul K. Wotton, Ph.D., Shishir Gadam, Ph.D., and Young K. Hong M.D. The SAB will play a pivotal role in advancing Made's vision to redefine cell therapy manufacturing and testing. By bringing together multi-disciplinary leaders experienced across the domain of cell therapy product translation, bioprocess and analytical technologies, and regulatory and clinical application, the Board will provide strategic guidance to strengthen Made's CDMO platform and accelerate innovation for its customers. Their insights will help drive strategic initiatives at Made focused on lowering the cost of goods (COGS) for cell therapies and enabling partners to deliver more accessible, reliable, and transformative therapies to patients globally. Made Scientific plans to further expand the SAB later this year. "The establishment of our Scientific Advisory Board marks a pivotal moment in our commitment to innovation," said Syed T. Husain, Chairman and CEO of Made Scientific. "Miguel, Paul, Shishir, and Young each bring world-class expertise across cell therapy, manufacturing science, commercialization, and clinical practice. Their guidance will directly shape our service priorities, ensuring we deliver advanced, accessible, and scalable solutions for patients globally." ABOUT MIGUEL FORTE Miguel Forte, M.D., Ph.D., is CEO of Kiji Therapeutics and President of the International Society for Cell & Gene Therapy (ISCT). Prior to joining Kiji Therapeutics, he was CEO of Bone Therapeutics and Zelluna Immunotherapy, and CMO/COO of TxCell. Dr. Forte also served at the European Medicines Agency (EMA) and holds leadership roles with the Alliance for Regenerative Medicine. He earned his M.D. from the University of Lisbon and Ph.D. from the University of Birmingham. ABOUT PAUL K. WOTTON Paul K. Wotton, Ph.D., currently serves as CEO and Chairman of RBL LLC, a Houston-based biotech accelerator, and Executive Director of the Biotech Launch Pad at Rice University. He also serves on the boards of Vericel Corporation, Cynata Therapeutics, Morphocell Technologies, and Combined Therapeutics. Dr. Wotton's past executive leadership includes CEO roles at Obsidian Therapeutics, Sigilon Therapeutics (acquired by Eli Lilly), Ocata Therapeutics (acquired by Astellas), Antares Pharma, and Topigen Pharmaceuticals. He received his Ph.D. in Pharmaceutical Sciences from the University of Nottingham. ABOUT SHISHIR GADAM Shishir Gadam, Ph.D., is Chief Technical Officer at Marea Therapeutics and former Head of Technical Operations at Cargo Therapeutics, where he built manufacturing infrastructure and advanced novel CAR-T programs. Previously he was Global Head of Cell Therapy MS&T at Juno Therapeutics (acquired by Bristol Myers Squibb), playing a key role in launching two commercial CAR-T therapies. Dr. Gadam's earlier roles include biologics development at Genentech and Roche. He holds a Ph.D. in Biochemical Engineering from Rensselaer Polytechnic Institute. ABOUT YOUNG K. HONG Young K. Hong, M.D., is a dual board-certified general surgeon and surgical oncologist/hepatopancreatobiliary surgeon at Cooper University Hospital and MD Anderson Cancer Center at Cooper. He serves as Director of Clinical Research and Cellular Therapy, Assistant Director of Surgical Research, and Director of the Surgical Outcomes Research Group. Dr. Hong is site Principal Investigator for adoptive cellular therapy clinical trials in metastatic melanoma, head and neck, and non-small cell lung carcinoma. His lab studies epigenetic modulation of immunotherapy in pancreatic adenocarcinoma and hepatocellular carcinoma. He completed three fellowships, including the Clinical Immunotherapy and Surgical Oncology Fellowship at the NIH/NCI, and earned his M.D. from Virginia Commonwealth University School of Medicine and MPH in Health Policy from the University of Louisville. Dr. Hong is widely published in immunotherapy and surgical oncology and active on national research committees and editorial boards, including Annals of Surgical Oncology. With the launch of the SAB and continued investments in state-of-the-art manufacturing platforms, next-generation analytics, and experienced leadership, Made Scientific remains focused on its mission: Defy Limits. Deliver Results. For more information, visit madescientific.com or contact [email protected]. About Made Scientific Made Scientific is a leading US-based cell therapy contract development and manufacturing organization (CDMO) specializing in the development, manufacturing, and release of autologous and allogeneic cell therapy products for clinical-and-commercial supply. Operating from two U.S.-based manufacturing facilities, Made Scientific combines the agility and entrepreneurial spirit of a specialist CDMO with the global expertise and resources of GC Corporation of South Korea, a global leader in the pharmaceutical and biotechnology sectors. SOURCE Made Scientific, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Major companies in the dry powder inhaler market are focusing on innovation, developing products with muscarinic antagonists for the treatment of chronic obstructive pulmonary disease (COPD), and expanding their product portfolios. Muscarinic antagonists are drugs that inhibit the muscarinic acetylcholine receptor and are used to treat various illnesses, including COPD NEWARK, DE / ACCESSWIRE / December 5, 2024 / The Dry Powder Inhaler Market is poised for significant growth, with a market value of USD 20.83 billion in 2024, projected to climb to USD 29.95 billion by 2034, representing a steady CAGR of 3.70% over the forecast period. This growth is underpinned by rising prevalence of respiratory diseases such as asthma and COPD, combined with technological advancements in drug delivery systems.Regulatory approvals for patient-friendly inhalation devices, increasing awareness of chronic respiratory diseases, and a rising geriatric population are also boosting the adoption of dry powder inhalers globally. With the growing focus on reducing hospital stays and providing efficient home-care treatments, these devices are becoming an essential tool in respiratory disease management.Regionally, the market sees diverse opportunities. Emerging economies in Asia-Pacific demonstrate the fastest growth due to increasing healthcare expenditure and heightened awareness about respiratory health. Developed regions, particularly North America and Europe, continue to dominate the market due to their advanced healthcare infrastructure and strong presence of key industry players.The shift toward environmentally friendly propellants and the development of digitalized inhalers equipped with dose-tracking and usage monitoring are reshaping the landscape, offering additional revenue streams for manufacturers.With the utilization of dry powder inhalers in the treatment of a diverse range of diseases, the development of technologically innovative products is surfacing. These "smart technologies" are set to satisfy specific market requirements for the development of cost-effective drug products. The deep penetration of digital systems into the inhaler market has been advantageous in terms of ruling out several device and design errors. The implementation of microprocessors in inhalers for supporting patients with device usage and handling is positively impacting compliance and product satisfaction.The development of next-generation inhalers with the integration of smart technologies is likely to drive the growth of the dry powder inhaler market. The integration is set to establish a breakthrough in drug delivery with the primary basis being a tailored performance based on the patient's/user's variable breathing patterns.Technologically advanced dry powder inhalers with digitally enabled platforms along with a friendly user interface will help in preventing or compensating actuation errors that, in turn, will enhance compliance. The growth of digitally operated inhalers devices is also supported by the recent upsurge in digitalization in the healthcare and industrial sectors. This factor will drive the dry powder inhaler market.The dry powder inhalers are a preferred method of treatment of respiratory ailments over pressurized metered dose inhalers and nebulizers owing to the rising concerns related to the environmental impact of inhaler devices which utilize chloroflouro carbons as propellants.Thus, the production and design of dry powder inhalers is set to witness a growth over the forecast period, and is expected to offer product manufacturers or key players in the dry powder inhaler market with an optimistic growth opportunity.Request a Sample of this Report Now: https://www.fmisamplereport.com/sample/rep-gb-5150Key Takeaways from Market StudyMarket Growth: Projected to grow from USD 20.83 billion in 2024 to USD 29.95 billion by 2034, at a CAGR of 3.70%.Technology Focus: Smart inhalers and eco-friendly propellants are driving innovations in the market.Disease Prevalence: Rising cases of asthma and COPD are a key determinant of demand.Regional Growth: North America and Europe lead the market, while Asia-Pacific exhibits the highest growth rate.Segment Dominance: Capsule-based inhalers continue to capture a significant market share due to their ease of use and cost-effectiveness."Dry powder inhalers are witnessing a transformation driven by the convergence of healthcare and technology. The emergence of smart inhalers, coupled with increasing adoption in developing markets, positions the industry for robust growth over the next decade. Companies that can successfully innovate while addressing environmental concerns will lead the charge in shaping the future of this vital healthcare segment." SaysSabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.)What Are The Key Opportunities For Dry Powder Inhalers Manufacturers?Confounding problems are existent in clinical trials for dry powder inhalers, specifically, where the possibility of errors by patients with respect to inhaler handling can be high. Distinguishing handling errors by patients from existing clinical effects is complex, particularly in phase III trials where support to patients cannot be contracted.The impact of digital systems thus presents an opportunity to assist with monitoring and control over all phases of clinical studies. Digital technology can improve clinical outcomes by improving adherence and reducing patient errors through mobile applications connected to the device, which will deliver useful tools including reminders and step-based guidance for the appropriate technique of usage.On the other hand, medical providers can track patient compliance to the therapeutic regimen in real time. Additionally, the monitoring of symptoms and their worsening is registered along with the compliance tracker and it assists with the prevention of severe disease exacerbations, thus leading to a satisfying patient outcome.The development of inhalation products poses the possibility of significant errors for drug-device combinations related to the usage of the device by patients, variations in the delivery of drugs, as well as flawed data collection.These errors may deliver distorted information regarding the therapeutic efficacy of drug formulations and device-based effects in clinical trials. The introduction of programmed tools for use in clinical trials will contribute to an improved understanding of drug-device combinations and their efficiency.These tools may assist with enhanced data collection processes without being influenced by poor patient compliance as well as administration issues. These automated tools can include incorporated audio-based technologies and devices for monitoring medication compliance.Connected wearable devices can be beneficial in tracking patient activity and thus evaluating the effect on clinical efficacy with integrated companion applications to capture patient-reported outcomes.Thus, the change in the landscape of clinical trials is set to be positively impacted by the monitoring of data all through the product life cycle along with patient-reported data in real-time conditions, thus presenting an opportunistic growth for the dry powder inhaler market.What Are The Factors Restraining Demand For Dry Powder Inhalers?Technological advancements are progressively growing in terms of increasing novel and innovative, integrated, alternative good manufacturing practice-ready approaches, which are associated with next-generation analytical and modelling skills. However, regulations encompassing such progressions are yet to catch up with the developing complex clinical requirements.This trend is intensified by the acceleration of complexity and the cost of approval for the formulation of orally inhaled and nasal drug products and by the scientific disparity that still exists, particularly for locally acting dry powder inhaler products.Considering this, despite existing development, animal models are not applicable to humans and perceptive methods for assessing clinical efficiency along with in-vitro and in-vivo association for inhaled medicines are still inadequate.In this concern, the outcome of the clinical approach is intensely predisposed by the ambiguous correlation between efficiency and selected clinical endpoints. This risk is greater for therapies in which the pattern of deposition of the drug is directly associated with efficiency.In spite of thorough assessments and a focus on advances in device design as well as formulation, the impact on the patient in terms of their adherence to therapy, inspiration rate, and correct use of the inhaler are yet to be quantified. This poses a restrictive impact on the growth of the dry powder inhaler market, given the wide-ranging factors associated with the intensity of the impact of disease on the patient, affecting their inspiration rate.Country-wise InsightsWhat Makes the U.S. the Largest Market for Dry Powder Inhalers?The U.S. dominates the North American region with a total market share of about 90.5% in 2020, and is projected to continue experiencing high growth throughout the forecast period. U.S. is the most lucrative market for dry powder inhalers owing to the combination of a robust healthcare infrastructure accompanied with technologically advanced procedure, an increasing number of patients with respiratory disorders, strictly enforced guidelines by regulatory authorities pertaining to medical devices attributed with respiratory disorder therapeutics, and comparatively high government healthcare spending.Furthermore, due to the increased prevalence of asthma and other respiratory disorders, as well as the growing geriatric population, the dry powder inhaler market in the United States is expected to develop significantly over the next decade.Why is Spain Considered a Lucrative Market for Dry Powder Inhalers in Europe?Spain. is set to exhibit a CAGR of nearly 2.90% in the European dry powder inhaler market during the forecast period. The rising research and development activities to generate a sustainable base of drug delivery devices in the country as well as an established healthcare infrastructure are some of the factors aiding the growth of dry powder inhalers in the country.What Makes China an Emerging Market for Dry Powder Inhalers?China holds 38.9% share in the East Asia dry powder inhaler market in 2020, and is projected to increase at a CAGR rate of 5.4% during the forecast period. This growth is associated with the rising deployment of automated systems and devices into an integrated platform for patient monitoring as well as drug delivery devices, rising healthcare costs and rapidly improving medical infrastructure. All these factors are expected to drive market growth in the coming years in China.CountriesForecast CAGRs from 2024 to 2034India5.20%Indonesia4.7%Canada3.1%Spain2.90%France2.40%Competitive LandscapeThe dry powder inhaler market is marked by robust competition as both established pharmaceutical leaders and emerging biotech innovators vie to capture market share. Key players drive innovation by focusing on research and development, improving device functionality, and expanding the therapeutic scope of their products.Strategic collaborations, regulatory compliance, and technological progress are crucial factors shaping this competitive environment. With an increasing emphasis on sustainability and patient-centric solutions, companies strive to differentiate themselves in a rapidly evolving market. As global demand for respiratory medications rises, competition fuels innovation, propelling advancements in dry powder inhaler technologies.Product PortfolioGlaxoSmithKline Plc is a global leader in healthcare innovation, offering a wide range of pharmaceuticals, vaccines, and consumer health products. With a strong commitment to patient-focused solutions, GSK delivers cutting-edge therapies that enhance well-being and improve quality of life worldwide.AstraZeneca Plc is a renowned biopharmaceutical company focused on transforming healthcare through advanced treatments in respiratory, oncology, cardiovascular, and other critical areas. Leveraging research and collaboration, AstraZeneca addresses unmet medical needs to improve patient outcomes globally.Novartis AG redefines medicine with its diverse portfolio that spans pharmaceuticals, generics, and eye care. By harnessing cutting-edge technology and science, Novartis creates innovative solutions aimed at tackling the most urgent healthcare challenges and delivering better health outcomes.Key Companies ProfiledGlaxoSmithKline PlcAstraZeneca Plc;Novartis AG;Teva Pharmaceutical Industries Limited;Boehringer Ingelheim GmbH;Cipla Limited;Chiesi Farmaceutici S.p.A.;Elpen S.A.;Vectura Group Plc;Beximco Pharmaceuticals Ltd.;Hovione;AptarGroup, Inc.;Iconovo AB (Stevanato Group);Sava Healthcare Ltd.;MannKind Corporation;Mylan N.V;PharmaxisSegmentation Analysis of the Dry Powder Inhaler IndustryBy Product:Single Dose Dry Powder InhalersMulti Dose Dry Powder InhalersBy Indication:AsthmaChronic Obstructive Pulmonary Disease (COPD)Pulmonary Arterial HypertensionDiabetesCystic FibrosisBy Function:Manually Operated Inhaler DevicesDigitally Operated Inhaler DevicesBy End User:Institutional SalesHospital PharmaciesCancer ResearchOffice based Specialty ClinicsRetail SalesRetail PharmaciesDrug StoresMail Order PharmaciesBy Region:North AmericaLatin AmericaWestern EuropeEastern EuropeSouth Asia & PacificEast AsiaThe Middle East & AfricaAuthorSabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.Explore FMI's Extensive Coverage in the Healthcare Domain:The global respiratory inhaler devices market size is anticipated to attain an impressive valuation of USD 37,258.5 million in 2023 and is projected to reach USD 60,114.7 million by 2033The global Dry Eye Syndrome Treatment Market is estimated to capture a CAGR of 6.4% over the forecast period. The global market is worth USD 5,120 million in 2023The anticipated size of the metered dose inhalers market in 2022 was USD 25,208.9 million and is estimated to be USD 26,322.9 million in 2023.Expanding at a high CAGR of 8.2%, the global Dual and Multi-energy Computed Tomography (CT) Market is projected to increase from a valuation of USD 1.5 Billion in 2022 to USD 2.6 Billion by 2029.The positron emission tomography (PET) scanners market is estimated to be valued at USD 1.3 billion in 2023 and is rising to USD 2.1 billion by 2033.The global optical coherence tomography market size reached USD 1,311.70 million in 2023.The global photoacoustic tomography market is projected to reach USD 79.2 million in 2022.A 5.8% compound annual growth rate (CAGR) is projected for the global mobile tomography market from 2022 to 2032, with 2022 revenues of USD 295.2 Million and 2032 revenues of USD 595.1 Million.The global medical automation market is estimated to secure a valuation of USD 48,626.2 million in 2023 and reach up to USD 103,052.3 million by 2033.As per the analysis, the electronic medical record market is set to account for a current valuation of USD 18.82 billion in 2024.About Future Market Insights (FMI)Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai and has delivery centres in the United Kingdom, the United States, and India. FMI's latest market research reports and industry analysis helps businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.Join us as we commemorate 10 years of delivering trusted market insights. Reflecting on a decade of achievements, we continue to lead with integrity, innovation, and expertise.Contact UsFuture Market Insights Inc.Christiana Corporate, 200 Continental Drive,Suite 401, Newark, Delaware - 19713, USAT: +1-347-918-3531For Sales Enquiries: [email protected]Website:https://www.futuremarketinsights.comLinkedIn| Twitter| Blogs | YouTubeSOURCE: Future Market Insights, Inc.